A Protein-Based, Long-Acting HIV-1 Fusion Inhibitor with an Improved Pharmacokinetic Profile [PDF]
Pharmaceuticals, 2022 Recently, a series of highly effective peptide- or protein-based HIV fusion inhibitors have been identified. However, due to their short half-life, their clinical application is limited.
Wei Xu +8 more
doaj +4 more sources
Carbohydrate-binding protein from stinging nettle as fusion inhibitor for SARS-CoV-2 variants of concern [PDF]
Frontiers in Cellular and Infection Microbiology, 2022 Urtica dioica agglutinin (UDA) is a carbohydrate-binding small monomeric protein isolated from stinging nettle rhizomes. It inhibits replication of a broad range of viruses, including coronaviruses, in multiple cell types, with appealing selectivity.
Emiel Vanhulle +10 more
doaj +3 more sources
A Modified Fibronectin Type III Domain-Conjugated, Long-Acting Pan-Coronavirus Fusion Inhibitor with Extended Half-Life [PDF]
Viruses, 2022 The coronavirus disease 2019 (COVID-19) pandemic caused by infection of SARS-CoV-2 and its variants has posed serious threats to global public health, thus calling for the development of potent and broad-spectrum antivirals.
Qianyu Duan +7 more
doaj +2 more sources
HIV-1 Entry and Membrane Fusion Inhibitors [PDF]
Viruses, 2021 HIV-1 (human immunodeficiency virus type 1) infection begins with the attachment of the virion to a host cell by its envelope glycoprotein (Env), which subsequently induces fusion of viral and cell membranes to allow viral entry.
Tianshu Xiao, Yongfei Cai, Bing Chen
doaj +3 more sources
The Dual-Targeted Fusion Inhibitor Clofazimine Binds to the S2 Segment of the SARS-CoV-2 Spike Protein [PDF]
VirusesClofazimine and Arbidol have both been reported to be effective in vitro SARS-CoV-2 fusion inhibitors. Both are promising drugs that have been repurposed for the treatment of COVID-19 and have been used in several previous and ongoing clinical trials ...
Matthew R. Freidel +3 more
doaj +2 more sources
IgG Fc-Binding Peptide-Conjugated Pan-CoV Fusion Inhibitor Exhibits Extended In Vivo Half-Life and Synergistic Antiviral Effect When Combined with Neutralizing Antibodies [PDF]
Biomolecules, 2023 The peptide-based pan-coronavirus fusion inhibitor EK1 is in phase III clinical trials, and it has, thus far, shown good clinical application prospects against SARS-CoV-2 and its variants.
Xiaojie Su +7 more
doaj +2 more sources
A Five-Helix-Based SARS-CoV-2 Fusion Inhibitor Targeting Heptad Repeat 2 Domain against SARS-CoV-2 and Its Variants of Concern [PDF]
Viruses, 2022 The prolonged duration of the severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pandemic has resulted in the continuous emergence of variants of concern (VOC, e.g., Omicron) and variants of interest (VOI, e.g., Lambda).
Lixiao Xing +12 more
doaj +2 more sources
Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide [PDF]
Viruses, 2019 Identifying drug resistance mutations is important for the clinical use of antivirals and can help define both a drug’s mechanism of action and the mechanistic basis of resistance. Resistance mutations are often identified one-at-a-time by studying
Adam S. Dingens +3 more
doaj +2 more sources
Translation of Mycobacterium Survival Strategy to Develop a Lipo‐peptide based Fusion Inhibitor** [PDF]
Angewandte Chemie - International Edition, 2021 Avijit Sardar +2 more
exaly +2 more sources
Viruses, 2022 Human Immunodeficiency virus (HIV-1) fusion is mediated by glycoprotein-41, a protein that has not been widely exploited as a drug target. Small molecules directed at the gp41 ectodomain have proved to be poorly drug-like, having moderate efficacy, high ...
Li He +6 more
doaj +1 more source